Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults.
Southeast Asian J Trop Med Public Health
;
2004 Sep; 35(3): 697-701
Article
in English
| IMSEAR
| ID: sea-35061
ABSTRACT
This study was undertaken to compare the immunogenicity and reactogenicity of two vaccines based on the attenuated Oka-strain of Varicella zoster virus (VZV), in adolescents and young adults. One hundred and eighty-six subjects, aged 13 to 29 years, were randomized to one of two groups to receive a one- or a two-dose VZV vaccine. Pre- and post-vaccination blood samples were assayed for VZV-specific IgG. Solicited local and general symptoms, as well as unsolicited symptoms, were recorded post-vaccination. Seroconversion rates were 94.9% in the one-dose, and 100% in the two-dose, regimen. The two-dose vaccine elicited significantly higher geometric mean antibody titer, 392.5 vs 86.8 pfu. Transient local injection site pain was the most frequently-reported symptom per dose in both groups (one dose 48.9%; two-dose 32.8%). The two-dose vaccine regimen afforded the advantage of higher antibody titers and potential increased protection from disease, without significantly increased reactogenicity.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Thailand
/
Humans
/
Immunoglobulin G
/
Enzyme-Linked Immunosorbent Assay
/
Prospective Studies
/
Fluorescent Antibody Technique
/
Adolescent
/
Immunization Schedule
/
Treatment Outcome
/
Herpesvirus 3, Human
Type of study:
Controlled clinical trial
/
Observational study
Country/Region as subject:
Asia
Language:
English
Journal:
Southeast Asian J Trop Med Public Health
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS